The shares of the German chemical company Bayer have significantly dropped following a crucial legal development.

Despite an operating profit of 9.1 trillion Won ($6.8 billion) in the third quarter, which fell by nearly 13 percent compared to the previous quarter, investor expectations remained disappointed. The slowdown in growth and ongoing legal disputes have significantly shaken confidence in Bayer. Since the beginning of the year, the company's shares have fallen by nearly 19 percent, reducing the market capitalization to approximately 26.77 billion Euros.

The Chairman of Bayer, Werner Baumann, recently commented on the current challenges: "We are in a difficult phase and are working intensively to stabilize our position and regain the trust of our stakeholders." Despite investments of over $60 billion in acquisitions over the past two years, Bayer continues to face the complex task of reducing debt and restructuring the diverse business segments in agriculture, pharmaceuticals, and consumer health.

The decision of the Washington Supreme Court gives Monsanto the opportunity to appeal the verdict and defend against the allegations made.

Analysts from Jefferies warn of significant financial losses if further negative rulings occur. "The risks of a multi-billion-dollar burden are real and could put additional pressure on Bayer's already weakened market position," according to the analyst. This assessment reflects concerns about the company's long-term profitability and competitiveness in an increasingly competitive market.

In addition to the legal issues, Bayer faces the challenge of adapting its business strategy while managing structural changes within the company. Shifting to more sustainable and innovation-driven business models will be crucial for strengthening market position and seizing future growth opportunities.